Multiple MyelomaMultiple myeloma, a cancer of the bone marrow, is becoming more common as our population ages.
John Theurer Cancer Center has one of the largest myeloma programs in the world. We are one of just a few treatment centers in the nation offering a dedicated team of experts for all stages of multiple myeloma. Patients come to us for highly personalized care and advanced treatment options they won’t find anywhere else.
Diagnosing Your Exact Type of Multiple Myeloma
Our doctors are among a group of researchers that studies the molecular make-up of myelomas. In fact, they published the first complete genomic portrait of multiple myeloma. We continue to advance our understanding to make the most detailed diagnosis possible.
We begin by performing specialized imaging and molecular and genetic analysis of your cancer. This way we can match you with the most appropriate therapy. This precision medicine approach ensures that you receive the therapy that is best suited for your multiple myeloma and offers the greatest chance of success.
Advanced Medical Therapies
You have access to the most advanced medical therapies for multiple myeloma. Our doctors’ research has led to some of the most important drugs used to treat multiple myeloma. These include thalidomide, lenalidomide, pomalidomide, bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, isatuximab, panobinostat, belantamab and selinexor.
CAR T-Cell Therapy
John Theurer Cancer Center is one of the few sites in the world offering CAR T-cell therapy for multiple myeloma. CAR T-cell therapy requires specialized expertise. Clinical trials of CAR T-cell treatment in other blood cancers have shown that in patients whose cancer returned after prior treatment, CAR T-cell therapy helped them achieve remission that lasted for years. Learn more about CAR T-Cell therapy.
John Theurer Cancer Center’s team has been involved in the development of advanced immunotherapy for multiple myeloma. Immunotherapy uses your body’s own immune system to find and destroy your cancer. These include CAR T-cell therapy, antibody drug conjugates and T-cell engagers, as well as checkpoint inhibitors — all of which will be mainstays of myeloma care into the future.
Personalized Monitoring for Pre-Myeloma
Some people have conditions that can turn into multiple myeloma. If you have been diagnosed with smoldering multiple myeloma or MGUS (monoclonal gammopathy of undetermined significance), we can customize a surveillance program for you.
Our doctors can monitor you and let you know if or when you may benefit from treatment. We also offer clinical trials that look at your immune system and other predictors of the best time to start treatment.
Stem Cell Transplantation
John Theurer Cancer Center has one of the largest blood and marrow stem cell programs in the country, with physicians who specialize in stem cell transplants for multiple myeloma. We perform more than 250 transplants for multiple myeloma each year, and the most transplants using donor stem cells (allogenic) for multiple myeloma than any other center in our region.
Our research focuses on reducing the complications of stem cell transplant and lowering the risk of cancer recurrence. We are the first team in the world to combine checkpoint inhibitors (drugs that work by inhibiting the proteins cancer cells use to evade detection by the immune system) after transplant. Our Blood and Marrow Stem Cell Transplant Program.
John Theurer Cancer Center has physicians whose only focus is multiple myeloma. We bring together all the multiple myeloma experts you may need. Your team includes experts in hematology/medical oncology, immunology, stem cell transplantation, infectious diseases, pathology, radiation oncology, orthopedics and nursing.
Why Choose John Theurer Cancer Center for Multiple Myeloma Treatment
For more than three decades, John Theurer Cancer Center has had physicians whose only focus is multiple myeloma. Our collective expertise in treating multiple myeloma is unsurpassed in the region.
Our doctors and scientists have been at the forefront of today’s most important drugs, immunotherapies and stem cell treatment protocols used to treat multiple myeloma.
We are a member of the Multiple Myeloma Research Consortium (MMRC), a group dedicated to accelerating the development of innovative therapies for multiple myeloma.